GlassScriptPhysician profile
Stanley A Brosman
NPI 1255416335
$6,913.17
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $676 · 2021: $1,276 · 2022: $1,575 · 2023: $1,607 · 2024: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $851.77 | 2019-2024 | Erleada |
| Pfizer INC. | $779.58 | 2019-2024 | |
| Astellas Pharma US INC | $755.87 | 2019-2023 | Myrbetriq, Xtandi |
| Myriad Genetic Laboratories, INC. | $592.29 | 2020-2024 | Prolaris |
| Blue Earth Diagnostics | $380.52 | 2019-2024 | |
| Coloplast Corp | $362.47 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $286.53 | 2021-2024 | Pylarify |
| Antares Pharma, INC. | $248.56 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $235.44 | 2022-2024 | Botox |
| Sun Pharmaceutical Industries INC. | $208.03 | 2019-2023 | Yonsa |
| Sumitomo Pharma America, INC. | $190.06 | 2023-2024 | Orgovyx, Gemtesa |
| Acerus Pharmaceuticals Corporation | $179.80 | 2020-2022 | |
| Myovant Sciences INC. | $170.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.86 | 2020-2024 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $147.38 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Brosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.